DG DISPATCH - AUA: Prostate cancer brachytherapy results in high cure rate
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AUA: Prostate cancer brachytherapy results in high cure rate

By Emma Patten
Special to DG News

ATLANTA, GA -- May 4, 2000 -- A 12-year follow-up study indicates that brachytherapy, the implantation of tiny radioactive seeds in the prostate, is a highly effective treatment for prostate cancer patients.

The findings were presented Wednesday (May 3) by Haakon Ragde, MD, from the Northwest Prostate Institute, in Seattle, WA, at the American Urological Association's 95th annual conference, in Atlanta, GA.

The researchers found that high-risk prostate cancer patients treated with a combination of external beam radiation and prostate brachytherapy displayed an overall cure rate of 70 percent after 12 years.

Dr. Ragde and colleagues examined 229 patients with prostate cancer at the clinical stages T1-T3, low to high Gleason grade, who were treated between January 1987 and September 1989. Of these patients, 147 received radioactive iodine brachytherapy alone, and the remaining 82 patients, who were at higher risk of extraprostatic extension, were also treated with external beam irradiation to the pelvis.

Of the 215 patients with sufficient follow-up, 66 percent of patients receiving brachytherapy alone and 69 percent of patients receiving brachytherapy and external beam irradiation remained clinically and biochemically free of disease at last follow-up. Combined, the two groups displayed an overall cure rate of 70 percent.

"Prostate cancer patients who were treated with transperineal brachytherapy showed a cure rate comparable to surgery. This strongly demonstrates the therapeutic value of prostate brachytherapy," noted Dr. Ragde. "Our cure rate for high risk patients is by far the best ever reported for such patients," he added.

Dr. Ragde also pointed out that "conformal prostate brachytherapy is poised to assume a major role in modern medicine and may well serve as a model for cancer treatments at other body sites."

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities